NICE recommends Rhythm’s Imcivree for rare genetic obesity disorder

Rhythm expects Imcivree will be available on the NHS in England and Wales within the next three months.

May 23, 2024 - 04:00

NICE recommends Rhythm’s Imcivree for rare genetic obesity disorder

Rhythm expects Imcivree will be available on the NHS in England and Wales within the next three months.

Read the original article

Tags:

Previous Article

AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio

No nitrosamines: How parenteral packaging is evolving to meet today’s E&L challe...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Over 20,000 UK businesses at risk of Chinese espionage, warns MI5 chief

Over 20,000 UK businesses at risk of Chinese espionage,...

Oct 21, 2023

Tango Therapeutics’ IND application for TNG260 receives FDA clearance

Tango Therapeutics’ IND application for TNG260 receives...

Apr 3, 2023

Boehringer Ingelheim offers Humira biosimilar at 92% discount

Boehringer Ingelheim offers Humira biosimilar at 92% di...

Jul 20, 2024